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Original article 
 
 
Neoadjuvant chemoradiation and pancreaticoduodenectomy for 
initially locally advanced head pancreatic adenocarcinoma 
    
O. Turrini MD*, F. Viret MD**, L. Moureau MD°, J. Guiramand MD*, V. Moutardier MD*, B. Lelong MD*, 
M. Giovannini MD*** and JR. Delpero MD* 
 
Departments of *Surgical Oncology, **Medical Oncology, ***Endoscopy and °Radiotherapy Institut 
Paoli-Calmettes and Université de la Méditerranée Marseille, France. 
 
Corresponding author:  Olivier Turrini  
    Institut Paoli-Calmettes  
    232 Bd de Sainte Marguerite  
    13009 Marseille, France. 
Telephone number:  0491223660 
Fax number:   0491223550 
Email address:   oturrini@yahoo.fr 
   turrinio@marseille.fnclcc.fr 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ARTICLE IN PRESS
 2
 
Abstract 
 
BACKGROUND: The most accepted treatment for locally advanced pancreatic adenocarcinoma 
(LAPA) is chemoradiotherapy (CRT). We sought to determine the benefit of pancreaticoduodenectomy 
(PD) in patients with LAPA initially treated by neoadjuvant CRT. 
METHODS: From January 1996 to December 2006, 64 patients with LAPA (borderline, n=49; 
unresectable, n=15) received 5-fluorouracil-cisplatin-based CRT. Of the 64 patients, 47 had 
progressive disease at restaging. Laparotomy was performed for 17 patients, and PD was performed 
in 9 patients (resected group). Fifty-five patients had CRT followed by gemcitabine-based 
chemotherapy (unresected group). 
RESULTS: The median survival and overall 5-years survival duration of all 64 patients were 14 
months and 12%, respectively. The mean delay between diagnosis and surgical resection was 5.5 
months. Mortality and morbidity from PD were 0% and 33%, respectively. The median survival of the 
resected group versus the unresected group was 24 months vs. 13 months. Three specimens 
presented a major pathological response at histological examination. No involved margins were found 
and positive lymph nodes were found in one patient. Resected patients developed distant metastases. 
CONCLUSIONS: PD after CRT was safe and resected patients had interesting survival rates. 
However, resected patients developed metastatic disease and new neoadjuvant regimens are needed 
to improve the survival of these patients.   
 
Key words: pancreatic adenocarcinoma, locally advanced, neoadjuvant, chemoradiation 
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Introduction 
Resection and perioperative treatment for patients with resectable pancreatic adenocarcinoma has 
improved survival over the last two decades but overall patient survival remains poor1,2. At the time of 
diagnosis, tumors are classified according to radiological findings: the improvement of helical dual 
phase scanning sensitivity and surgeons’ experience has advanced the classification from resectable 
and unresectable to resectable, borderline and unresectable3,4. Locally advanced pancreatic 
adenocarcinoma (LAPA), comprising both borderline and unresectable tumors, is characterized by the 
abutment or invasion of major vascular structures preventing surgeons from achieving optimal R0 
resection. Thus, patients diagnosed with LAPA are likely to be spared from surgery; rapid disease 
progression and poor clinical status means patients undergo exclusively medical treatment with poor 
survival rates5,6. However, patients diagnosed with non-metastatic LAPA with a good clinical status are 
likely to undergo chemoradiation (CRT)7. Although it is impossible for patients with arterial 
adhesion/invasion to undergo resection, venous involvement proved not to be a contraindication to 
resection8-13. Thus, despite low resection rates, several reports showed interesting results on overall 
survival14-20 after pancreaticoduodenectomy (PD) for LAPA. Moreover, not resecting the tumor 
exposed patients to recurrent biliary and digestive obstruction, increasing the incidence of 
uncontrollable pain and a poor quality of life21. In 1996, we started a neoadjuvant approach for 
pancreatic adenocarcinoma and we sought to determine the impact of PD after CRT in patients initially 
diagnosed with LAPA. 
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Methods 
Patient selection 
Between January 1996 and December 2006, 151 patients were diagnosed with a histologically 
proven non-metastatic adenocarcinoma of the pancreatic head and were considered eligible for 
neoadjuvant CRT. Pancreatic cancer was staged by physical examination, chest radiography, biopsy 
(fine needle aspiration with Wilson-Cook 22 gauge, 8cm needles) obtained by endoscopy under 
ultrasound guidance (EUS) (Pentax-Hitachi, Hamburg, Germany), and thin-section contrast-
enhanced helical dual phase scanning (CT scan). Patients with adenocarcinoma of the tail or neck of 
the pancreas, intraductal papillary mucinous adenocarcinoma, tumors of neuroendocrine origin or 
with carcinoma of the duodenum, distal common bile duct, or ampulla of Vater were excluded from 
this study. Patients having any major comorbidity precluding consideration of pancreatic surgery 
were also excluded. Resectability was assessed by both surgeons and radiologists and tumors were 
classified as resectable (n=87), borderline (n=49) and unresectable (n=15) (table 1). Biliary stenting 
by a 10-French plastic stent was performed before or during neoadjuvant CRT if any sign of 
cholangitis or complete biliary obstruction occurred.  
 
Primary treatment and restaging (n=64) 
Neoadjuvant CRT consisted of standard-fractionation radiotherapy (45 Gy for 5 weeks) combined with 
concurrent chemotherapy, including continuous infusion of 5-fluorouracil (650 mg/m2 on Days 1–5 and 
Days 21–25) accompanied by a cisplatin bolus (80 mg/d/m2 on Days 2 and 22). World Health 
Organization (WHO) Grades 2, 3 or 4 toxicity events were recorded during CRT and 4 patients (6%) 
experienced grade 3 toxicity. All patients were restaged after completion of chemoradiation and 
radiologic tumor response was determined using Response Evaluation Criteria In Solid Tumors 
(RECIT) criteria for staging. Forty six patients had progressive disease (metastases, n=25; increase in 
gross tumor size, n=12; carcinomatosis, n=9. The serum level of CA19-9 was not retained to spare 
patients from explorative laparotomy if no distant metastasis was detected at restaging. The 
laparoscopic approach was routinely performed and one patient was identified with carcinomatosis. 
 
Explorative laparotomy (n=17)  
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Laparoscopic evaluation of vascular involvement using echolaparoscopy was not used routinely 
because: a) CRT and/or the presence of metallic biliary stents made it difficult to achieve an 
appropriate analysis of the tumor boundaries,  b) endosonographic encasement did not allow for 
diagnosis of the real features of the involvement (post-radic or tumoral), and c) biopsy under 
echolaparoscopy of perivascular tissue was hazardous if needed. During laparotomy, 4 explorative 
steps were always carried out. Step one: careful examination of the entire abdomen using a 
laparoscopic approach. Step two: dissection of the superior mesenteric artery (SMA) on its left side, 
pulling down the duodenojejunal angle. The SMA was then completely dissected on both face and 
multiples biopsies were performed to prevent any tumoral adhesion and R1/R2 resection. This 
allowed for a complete lymph node resection if required (SMA lymphadenectomy). Step tree: 
dissection of the inferior side of the pancreas, including entire dissection of the portal vein (PV) and 
the superior mesenteric portal vein (SMPV) confluent. Step four: dissection of the upper side of the 
pancreas to identify encasement of the hepatic artery (HA) or celiac trunk CT. This allowed for the 
complete resection of the lymph nodes of the corresponding area. Multiple perivascular biopsies 
were routinely performed to distinguish post-radic tissue with tumor involvement. No false positive or 
negative results were noted after frozen section analyses. Patients underwent a resection with the 
intention of a cure if the biopsies were negative. 
 
Resection (n=9) 
Nine patients (resected group) had a PD with extended lymphadenectomy. Two patients needed an 
enlarged resection adjacent to nearby organs (right colon, n=2). We routinely performed staining of 
the pancreatic section, posterior margin and PV bed margin in the operating room. Pathological 
examination included the margin status, lymph node involvement, gross tumor size and perineural 
invasion. The absence of residual cancer in the resected specimen (sterilized specimen) after CRT 
was defined as a complete pathological response (ypT0). Minimal residual disease was defined by 
presence of tumor < 2mm in the resected specimen. No resected patients had adjuvant 
chemotherapy. Fifty-five patients (unresected group) had CRT followed by systemic gemcitabine-
based chemotherapy for an unresectable tumor. 
 
Follow-up and statistical analysis  
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All living patients were evaluated by a combined medical and surgical team at 1, 4 and 6 months post-
operatively, and every year thereafter. Physical examination, thin-section contrast-enhanced helical 
dual phase CT scan and tumor markers (CEA, CA 19-9) were routinely obtained in follow-up. The type 
of recurrence was noted (metastasis, carcinomatosis or local recurrences). Survival was measured 
from the date of diagnosis to the date of death or January 1, 2008, the censor date. Survival was 
examined using the Kaplan-Meier method. Statistical comparisons were conducted using log rank 
tests; p<0.05 was considered to be statistically significant.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ARTICLE IN PRESS
 7
Results 
Entire population, restaging (n=64) 
No patients were lost to follow-up, with a mean follow-up of 38 months (range 12-117). Overall 1, 3 
and 5 years survival of all 64 patients who underwent primary treatment and restaging were 58%, 12% 
and 12%, respectively; the median overall survival was 14 months. The mean delay between 
diagnosis and surgical resection was 5.5 months (range 3-8). In patients without distant disease found 
at restaging (n=34), local tumor progression was documented in 12 patients, stable disease was 
documented in 16 patients, and partial remission was documented in one patient. 
Patients who underwent explorative laparotomy (n=17) and resected patients (n=9) 
The characteristics of patients having an explorative laparotomy are summarized in Table 2. 
Pathological findings and outcomes of resected patients (n=9) are summarized in Table 3.  
Mortality and morbidity were 0% and 33% (gastric emptying, n=2; pancreatic fistula, n=1), 
respectively. Overall 1 and 3 years survival rates of the resected group versus the unresected group 
were 78% vs. 53% (p=0.04) and 65% vs. 3% (p<0.01), respectively. The median survival of the 
resected group vs. the unresected group was 24 months vs. 13 months (figure 1), respectively. 
Pathological findings (table 3) 
Three patients had a sterilized (ypT0, n=1) or minimal residual disease (n=2) at histological 
examination. No involved margins were found. Positive lymph nodes were found in 1 patient. 
Recurrences (table 3) 
Four patients of the resected group developed distant metastatic recurrence. Four patients were alive 
without recurrence with a mean follow up of 32 months. One patient died of another cause (myocardial 
infarction) than pancreatic cancer during follow up. 
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Discussion 
Using strict CT-scan criteria to evaluate LAPA, complete resection was achieved in only 14% of 
patients. However, the overall survival time seemed to be improved due to the local effect of CRT (no 
margin involved, downstaging of tumors) and time-selection sparing patients with progressive disease. 
Resection rate 
Resection rates vary from 13% to 63% in the literature (table 4) due to a) CT-scan and endoscopic 
criteria chosen to define LAPA and/or b) the fact that studies focus on borderline tumors. Arterial 
involvement remains a contraindication for resection due to the high morbidity involved and low benefit 
gained with regards to survival. On the other hand, several reports8-13 showed that 
resection/reconstruction of the PV or SMPV confluent were safe and improved survival. Therefore, 
tumors in contact with major venous vasculature without circumferential encasement, PV thrombosis 
or large involvement of the SMPV confluent must be considered resectable tumors. Those findings 
help to optimize the resectability classification: pancreatic head adenocarcinoma could be staged as 
resectable, borderline or unresectable. However, the total encasement of the SMA or CT (previously 
an unresectable tumor) was associated with a poor resection rate compared to a case of tumor 
abutment (previously classified as a borderline tumor) (7% versus 16%, respectively).  
Survival 
The median survival of patients with LAPA was poor (14 months) as reported in table 4. However, 
patients with LAPA who underwent curative PD had comparable median survival times than patients 
with initially resectable tumors22. However, there were two major criticisms of our study. Firstly, the 
mean delay between diagnosis and surgery was over 5 months, higher than we reported23 for patients 
with initially resectable tumors. In the early experience of the series, the persistence of periarterial 
thickness at restaging was concerning and patients underwent a supplementary observation time 
before undergoing a laparotomy. In 2005, Sa Cuhna et al24 showed that the thickness around SMA or 
celiac axis could be treated by CRT and did not preclude a laparotomy. Thus, we scheduled surgery 5 
weeks after completion of CRT, as for neoadjuvant CRT for resectable tumors. We supposed that our 
additional time-selection of CRT participated to spare patients with disease progression and identified 
good candidates for surgery. Secondly, the small number of patients in the resected group precluded 
from emphatic conclusions.  Nevertheless, our findings seem to be comparable to other series and we 
found that patients who underwent PD for LAPA did have an improved survival time.   
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Future strategies 
CRT associated with PD enabled the optimal local control of the disease, as confirmed by tumor 
downstaging (one patient with ypT0 stage tumor and 2 patients with minimal residual disease), margin 
free resections and no identified local recurrences25-28. However, outstanding local control did not 
prevent distant recurrences and 4 resected patients experienced metastatic spread. On the other 
hand, 53% of patients with initially diagnosed localized disease developed metastasis during CRT and 
consequently underwent inappropriate local treatment. We strongly advocate that systemic 
chemotherapy should be used in the management of patients diagnosed with apparently non-
metastatic LAPA.  We suggest that a neoadjuvant approach should be preferred and should include 
gemcitabine-based chemotherapy and radiation therapy.  This makes sense, particularly since 
delayed recovery after surgery precludes adjuvant therapy in approximately 30% of patients who 
undergo elective PD as the initial treatment for pancreatic adenocarcinoma29,30. However, the best 
neoadjuvant regimen is still to be determined31. Recently, new neoadjuvant strategies have shown 
interesting results in resectable and locally advanced pancreatic cancer32. However, further studies 
are needed to determine the impact on the postoperative course and overall survival in resected 
patients with initially diagnosed LAPA. 
 
Conclusions 
Patients with pancreatic cancer should be discussed within a multidisciplinary staff setting to 
determine tumor resectability and decide on appropriate neoadjuvant treatment (drugs, doses, 
sequences and so on). Patients who underwent curative resection had comparable survival to patients 
with an initially resectable tumor. Thus, despite low resection rates, the opportunity for curative 
resection should not be refuted based on a CT-scan assessment. While waiting for more effective 
therapies besides gemcitabine and 5-FU, new neoadjuvant regimens have to be assessed in order to 
increase arguments for surgery as a last approach.  
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Table 2: characteristics of patients who underwent explorative laparotomy (n=17). 
 
Mean age (yo) 56 (range 37-70) 
Tumor size 3.4 (range 2.8-4.2) 
Ca19-9 levels (IU/ml)° 122.8 (range 2-423) 
Initial cause of LAPA classified 
PV / SMPV confluent involvement 
SMA / CA / HA involvement 
 
 
12  
7   
Delay diagnosis / surgery (months) 5.5 (range 3-8) 
Resected 
Tumor size (cm) 
Ca19-9 levels (IU/ml)° 
Operative duration (mn) 
Blood loss (mL) 
9  
3.2 (3-3.9) 
95.5 (range 8-253) 
447 (range 365-510) 
220 (range 50-720) 
Cause of non resection 
Arterial encasement 
Venous encasement 
 
3  
5  
(PV: Portal Vein 
 SMPV: Superior Mesenterico Portal Vein 
 CA:  Celiac Axis 
 SMA:  Superior Mesenteric Artery 
 HA: Hepatic Artery) 
(°CA 19-9 levels were measured at time of diagnosis / after correction of obstructive jaundice) 
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Table 3: characteristics of patients with LAPA who underwent pancreaticoduodenectomy. 
Patient 1 2 3 4 5 6 7 8 9 
Age 63 56 68 59 59 58 43 59 67 
Vessel involved PV PV CA PV+SMA PV PV SMA+CA PV+SMA PV 
Delay to surgery (months) 3 5 7 3 6 5 8 5 8 
CA 19-9 levels (IU/ml)° 15 110 253 185 8 29 139 14 89 
Vascular resection L. PV L. PV no no T. PV no no L. PV L.PV 
Operative duration (mn) 421 382 365 485 510 390 505 490 475 
Blood loss (ml) 150 120 50 380 720 120 80 210 160 
Specimen status - - - - - MRD MRD - Sterilized 
Nodes (positive/total) 0/11 0/9 0/17 0/6 1/5 0/18 0/5 0/7 0/10 
Positives margins no no    no no no no no no no 
Perineural invasion no yes yes yes yes no no yes no 
Recurrence -* Meta.* - Meta.* - - Meta.* Meta. - 
Morbidity no no PF no no GE no GE no 
Survival (months) 4 12 - 13 - - 27 - - 
(PV:  Portal Vein;  
 CA:  Celiac Axis 
 SMA:  Superior Mesenteric Artery 
L. PV: Lateral resection of portal vein 
T. PV: Troncular resection of portal vein 
MRD:  Minimal Residual Disease 
PF:  Pancreatic Fistula 
GE: Gastric Emprtying 
 *:  patient dead) 
(°CA 19-9 levels were measured at time of diagnosis / after correction of obstructive jaundice) 
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Table 4: patients receiving neoadjuvant CRT for LAPA. 
 
 year n Chemo. Resection rate Median survival 
resected 
(months) 
Median survival 
unresected 
(months) 
*Wanebo et al.14 2000 14 5 FU/cisplat 63% 19 - 
*Mehta et al.15 2001 15 5 FU 60% 30 8 
Ammori et al.16 2003 67 Gem 13% 17.6 11.9 
Aristu et al.17 2003 47 5FU/ cisplat 19% 23 10 
Massuco et al.18 2006 23 Gem 26% 20 12 
Lind et al. 19 2006 17 Ox/cap 47% 29 - 
*Katz et al.20 2008 160 Gem 41% 40 13 
Current series 2008 64 5 FU/cisplat 14% 24 13 
(*borderline series; Gem: gemcitabine-based chemoradiation; cisplat: cisplatin-based chemoradiation; ox: 
oxaliplatin; cap: capecitabine) 
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Table 1: allocation of patients with locally advanced pancreatic adenocarcinoma 
according to radiological findings. 
 
 
 Borderline  (n=49) Unresectable (n=15) 
SMA Tumor abutment ≤ 180° of the circumference  Encased > 180° 
CT / HA Short segment encasement / abutment  Encased with extension to the CA origin 
SMV / PV Short segment occlusion Occluded and no technical option for 
reconstruction 
(SMA: Superior Mesenteric Artery; CT: celiac trunk; HA: Hepatic Artery; SMV: Superior Mesenteric Vein; PV: Portal 
Vein) 
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Figure 1: overall survival of patients with Locally Advanced Pancreatic Adenocarcinoma (LAPA). 
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Log –rank test unresected vs. resected = 0.01 
 
Subjects at risk 
  0  12  24  36  48 
all patients 64  37  6  3  2 
unresected 55  29  3 
resected 9  8  4  2  1  
